Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Abd Alkhalik Basha, M., Abd El Aziz El Sammak, D., & El Sammak, A. A. (2017). Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound. Clin Radiol, 72(10), 901 e901-901 e911. doi:10.1016/j.crad.2017.05.019

Abdella, H., Shaker, M. K., Montasser, I. F., Sobhi, M., Aly, H., Sayed, A., . . . El Dorry, A. (2018). Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis. Indian J Gastroenterol, 37(2), 127-132. doi:10.1007/s12664-018-0830-4

Abdelmaksoud, A. H., Mandooh, S., Nabeel, M. M., Elbaz, T. M., Shousha, H. I., Monier, A., . . . Abdelaziz, A. O. (2017). Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients. Asian Pac J Cancer Prev, 18(1), 183-188. doi:10.22034/APJCP.2017.18.1.183

Abe, H., Aida, Y., Ishiguro, H., Yoshizawa, K., Miyazaki, T., Itagaki, M., . . . Aizawa, Y. (2013). Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World J Gastroenterol, 19(1), 78-85. doi:10.3748/wjg.v19.i1.78

Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., . . . Kelley, R. K. (2018). Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med, 379(1), 54-63. doi:10.1056/NEJMoa1717002

Agopian, V. G., Morshedi, M. M., McWilliams, J., Harlander-Locke, M. P., Markovic, D., Zarrinpar, A., . . . Busuttil, R. W. (2015). Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg, 262(3), 536-545; discussion 543-535. doi:10.1097/sla.0000000000001384

Aleksandrova, K., Bamia, C., Drogan, D., Lagiou, P., Trichopoulou, A., Jenab, M., . . . Trichopoulos, D. (2015). The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr, 102(6), 1498-1508. doi:10.3945/ajcn.115.116095

Aleman, S., Rahbin, N., Weiland, O., Davidsdottir, L., Hedenstierna, M., Rose, N., . . . Hultcrantz, R. (2013). A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis, 57(2), 230-236. doi:10.1093/cid/cit234

Allander, T., Gruber, A., Naghavi, M., Beyene, A., Soderstrom, T., Bjorkholm, M., . . . Persson, M. A. (1995). Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet, 345(8950), 603-607. 

Altekruse, S. F., McGlynn, K. A., Dickie, L. A., & Kleiner, D. E. (2012). Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology, 55(2), 476-482. doi:10.1002/hep.24710

Alvarez, M. A., Cirera, I., Sola, R., Bargallo, A., Morillas, R. M., & Planas, R. (2011). Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol, 45(10), 906-911. doi:10.1097/MCG.0b013e3182284e13

Amodio, P., Bemeur, C., Butterworth, R., Cordoba, J., Kato, A., Montagnese, S., . . . Morgan, M. Y. (2013). The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology, 58(1), 325-336. doi:10.1002/hep.26370

Anatelli, F., Chuang, S. T., Yang, X. J., & Wang, H. L. (2008). Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol, 130(2), 219-223. doi:10.1309/WMB5PX57Y4P8QCTY

Antoury, C., Lopez, R., Zein, N., Stoller, J. K., & Alkhouri, N. (2015). Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease. World J Hepatol, 7(10), 1427-1432. doi:10.4254/wjh.v7.i10.1427

Arii, S., Yamaoka, Y., Futagawa, S., Inoue, K., Kobayashi, K., Kojiro, M., . . . Yamada, R. (2000). Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology, 32(6), 1224-1229. doi:10.1053/jhep.2000.20456

Ariizumi, S., Yamamoto, M., Ohtsubo, T., Katsuragawa, H., Katagiri, S., & Takasaki, K. (2005). Step classification is useful for the determination of indications for systematized hepatectomy in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg, 12(5), 371-377. doi:10.1007/s00534-005-1003-2

Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A., Feldstein, A. F., & Zein, N. N. (2010). The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 51(6), 1972-1978. doi:10.1002/hep.23527

Aube, C., Oberti, F., Lonjon, J., Pageaux, G., Seror, O., N'Kontchou, G., . . . Group, C. (2017). EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int, 37(10), 1515-1525. doi:10.1111/liv.13429

Bager, P. (2017). The assessment and care of patients with hepatic encephalopathy. Br J Nurs, 26(13), 724-729. doi:10.12968/bjon.2017.26.13.724

Bang, C. S., & Song, I. H. (2017). Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol, 17(1), 46. doi:10.1186/s12876-017-0606-9

Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., . . . et al. (1992). Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology, 16(1), 132-137. 

Bartosch, B., Thimme, R., Blum, H. E., & Zoulim, F. (2009). Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol, 51(4), 810-820. doi:10.1016/j.jhep.2009.05.008

Batlle, A. M. (1993). Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis. J Photochem Photobiol B, 20(1), 5-22. 

Batts, K. P., & Ludwig, J. (1995). Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol, 19(12), 1409-1417. 

Beasley, R. P., Hwang, L. Y., Lee, G. C., Lan, C. C., Roan, C. H., Huang, F. Y., & Chen, C. L. (1983). Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet, 2(8359), 1099-1102. 

Benkel, I., Wijk, H., & Molander, U. (2012). Loved ones obtain various information about the progression of the patient's cancer disease which is important for their understanding and preparation. Am J Hosp Palliat Care, 29(1), 64-69. doi:10.1177/1049909111412579

Bennett, S., Pigott, A., Beller, E. M., Haines, T., Meredith, P., & Delaney, C. (2016). Educational interventions for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev, 11, Cd008144. doi:10.1002/14651858.CD008144.pub2

Bertino, G., Ardiri, A., Malaguarnera, M., Malaguarnera, G., Bertino, N., & Calvagno, G. S. (2012). Hepatocellualar carcinoma serum markers. Semin Oncol, 39(4), 410-433. doi:10.1053/j.seminoncol.2012.05.001

Bharat, A., Brown, D. B., Crippin, J. S., Gould, J. E., Lowell, J. A., Shenoy, S., . . . Chapman, W. C. (2006). Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg, 203(4), 411-420. doi:S1072-7515(06)00940-9 [pii]10.1016/j.jamcollsurg.2006.06.016

Bianchi, G., Loguercio, C., Sgarbi, D., Abbiati, R., Brunetti, N., De Simone, T., . . . Marchesini, G. (2003). Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis, 35(1), 46-54. 

Bioulac-Sage, P., Laumonier, H., Couchy, G., Le Bail, B., Sa Cunha, A., Rullier, A., . . . Saric, J. (2009). Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology, 50(2), 481-489. doi:10.1002/hep.22995

Biselli, M., Conti, F., Gramenzi, A., Frigerio, M., Cucchetti, A., Fatti, G., . . . Trevisani, F. (2015). A new approach to the use of alpha-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer, 112(1), 69-76. doi:10.1038/bjc.2014.536

Blazeby, J. M., Currie, E., Zee, B. C., Chie, W. C., Poon, R. T., & Garden, O. J. (2004). Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer, 40(16), 2439-2444. doi:10.1016/j.ejca.2004.06.033

Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., . . . Sherman, M. (2001). Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 48(2), 251-259. 

Bower, J. E. (2019). The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms. Cancer, 125(3), 353-364. doi:10.1002/cncr.31790

Brancatelli, G., Federle, M., Grazioloi, L., & Carr, B. (2002). Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathological findings in 39 U.S. residents. Radiology, 222, 89-94. 

Bravi, F., Bosetti, C., Tavani, A., Gallus, S., & La Vecchia, C. (2013). Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol, 11(11), 1413-1421 e1411. doi:10.1016/j.cgh.2013.04.039

Bravi, F., Tavani, A., Bosetti, C., Boffetta, P., & La Vecchia, C. (2017). Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev, 26(5), 368-377. doi:10.1097/CEJ.0000000000000252

Brener, S. (2015). Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ont Health Technol Assess Ser, 15(18), 1-45. 

Brown, C. G. (2014). Screening and evidence-based interventions for distress in patients with cancer: nurses must lead the way. Clin J Oncol Nurs, 18 Suppl, 23-25. doi:10.1188/14.Cjon.S1.23-25

Bru, C., Maroto, A., Bruix, J., Faus, R., Bianchi, L., Calvet, X., . . . Rodes, J. (1989). Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci, 34(11), 1765-1769. 

Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J. C., . . . Rodes, J. (1996). Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology, 111(4), 1018-1022. 

Bruix, J., & Colombo, M. (2014). Hepatocellular carcinoma: current state of the art in diagnosis and treatment. Best Pract Res Clin Gastroenterol, 28(5), 751. doi:10.1016/j.bpg.2014.08.010

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., . . . Investigators, R. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389(10064), 56-66. doi:10.1016/S0140-6736(16)32453-9

Bruix, J., Sherman, M., & American Association for the Study of Liver, D. (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53(3), 1020-1022. doi:10.1002/hep.24199

Bruix, J., Sherman, M., & JM, L. (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol, 35, 421-430. 

Brunello, F., Veltri, A., Carucci, P., Pagano, E., Ciccone, G., Moretto, P., . . . Rizzetto, M. (2008). Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol, 43(6), 727-735. doi:10.1080/00365520701885481

Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnu, L., Mazzella, G., . . . Italian Association of the Study of the Liver, D. (2007). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology, 45(3), 579-587. doi:10.1002/hep.21492

Bruno, S., Zuin, M., Crosignani, A., Rossi, S., Zadra, F., Roffi, L., . . . Maisonneuve, P. (2009). Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol, 104(5), 1147-1158. doi:10.1038/ajg.2009.31

Brunocilla, P. R., Brunello, F., Carucci, P., Gaia, S., Rolle, E., Cantamessa, A., . . . Rizzetto, M. (2013). Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol, 30(1), 345. doi:10.1007/s12032-012-0345-2

Burke, S., Wurz, A., Bradshaw, A., Saunders, S., West, M. A., & Brunet, J. (2017). Physical Activity and Quality of Life in Cancer Survivors: A Meta-Synthesis of Qualitative Research. Cancers (Basel), 9(5). doi:10.3390/cancers9050053

Burrel, M., Reig, M., Forner, A., Barrufet, M., de Lope, C. R., Tremosini, S., . . . Bruix, J. (2012). Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol, 56(6), 1330-1335. doi:10.1016/j.jhep.2012.01.008

Caballeria, L., Pares, A., Castells, A., Gines, A., Bru, C., & Rodes, J. (2001). Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol, 96(4), 1160-1163. doi:10.1111/j.1572-0241.2001.03695.x

Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348(17), 1625-1638. doi:10.1056/NEJMoa021423

Cardell, K., Widell, A., Fryden, A., Akerlind, B., Mansson, A. S., Franzen, S., . . . Isaksson, B. (2008). Nosocomial hepatitis C in a thoracic surgery unit; retrospective findings generating a prospective study. J Hosp Infect, 68(4), 322-328. doi:10.1016/j.jhin.2007.12.008

Cardoso, A. C., Moucari, R., Figueiredo-Mendes, C., Ripault, M. P., Giuily, N., Castelnau, C., . . . Marcellin, P. (2010). Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol, 52(5), 652-657. doi:10.1016/j.jhep.2009.12.028

Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407(6801), 249-257. doi:10.1038/35025220

Carr, B. I., Kondragunta, V., Buch, S. C., & Branch, R. A. (2010). Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer, 116(5), 1305-1314. doi:10.1002/cncr.24884

Carr, B. I., & Pujol, L. (2010). Pain at presentation and survival in hepatocellular carcinoma. J Pain, 11(10), 988-993. doi:10.1016/j.jpain.2010.01.265

Cavazza, A., Caballeria, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., & Pares, A. (2009). Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology, 50(4), 1162-1168. doi:10.1002/hep.23095

Centis, E., Marzocchi, R., Di Domizio, S., Ciaravella, M. F., & Marchesini, G. (2010). The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis, 28(1), 267-273. doi:10.1159/000282101

Chandok, N., & Watt, K. D. (2010). Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc, 85(5), 451-458. doi:10.4065/mcp.2009.0534

Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., . . . Taiwan Hepatoma Study, G. (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst, 101(19), 1348-1355. doi:10.1093/jnci/djp288

Chang, W. T., Kao, W. Y., Chau, G. Y., Su, C. W., Lei, H. J., Wu, J. C., . . . Lee, S. D. (2012). Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery, 152(5), 809-820. doi:10.1016/j.surg.2012.03.024

Chapman, W. C., Majella Doyle, M. B., Stuart, J. E., Vachharajani, N., Crippin, J. S., Anderson, C. D., . . . Brown, D. B. (2008). Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg, 248(4), 617-625. doi:10.1097/SLA.0b013e31818a07d4

Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012). Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer, 48(14), 2137-2145. doi:10.1016/j.ejca.2012.02.063

Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., . . . Guan, Z. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10(1), 25-34. doi:10.1016/S1470-2045(08)70285-7

Chie, W. C., Blazeby, J. M., Hsiao, C. F., Chiu, H. C., Poon, R. T., Mikoshiba, N., . . . Chiang, C. (2012). International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology, 55(4), 1122-1129. doi:10.1002/hep.24798

Chie, W. C., Yu, F., Li, M., Baccaglini, L., Blazeby, J. M., Hsiao, C. F., . . . Chiang, C. (2015). Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Qual Life Res, 24(10), 2499-2506. doi:10.1007/s11136-015-0985-8

Chiu, R. Y., Yap, W. W., Patel, R., Liu, D., Klass, D., & Harris, A. C. (2016). Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging. Can Assoc Radiol J, 67(2), 158-172. doi:10.1016/j.carj.2015.09.006

Choi, J. W., Chung, J. W., Lee, D. H., Kim, H. C., Hur, S., Lee, M., & Jae, H. J. (2018). Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol, 28(5), 2184-2193. doi:10.1007/s00330-017-5145-9

Choi, J. W., Kim, H. C., Lee, J. H., Yu, S. J., Kim, Y. J., Yoon, J. H., . . . Chung, J. W. (2017). Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol, 27(4), 1448-1458. doi:10.1007/s00330-016-4511-3

Choi, S. B., Park, J. S., Kim, J. K., Hyung, W. J., Kim, K. S., Yoon, D. S., . . . Kim, B. R. (2008). Early experiences of robotic-assisted laparoscopic liver resection. Yonsei Med J, 49(4), 632-638. doi:10.3349/ymj.2008.49.4.632

Chou, R., Cuevas, C., Fu, R., Devine, B., Wasson, N., Ginsburg, A., . . . Sullivan, S. D. (2015). Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Ann Intern Med, 162(10), 697-711. doi:10.7326/M14-2509

Chow, P. K. H., Gandhi, M., Tan, S. B., Khin, M. W., Khasbazar, A., Ong, J., . . . Asia-Pacific Hepatocellular Carcinoma Trials, G. (2018). SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol, 36(19), 1913-1921. doi:10.1200/JCO.2017.76.0892

Christian-Miller, N., & Frenette, C. (2018). Hepatocellular cancer pain: impact and management challenges. J Hepatocell Carcinoma, 5, 75-80. doi:10.2147/jhc.S145450

Ciccarelli, O., Lai, Q., Goffette, P., Finet, P., De Reyck, C., Roggen, F., . . . Lerut, J. (2012). Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int, 25(8), 867-875. doi:10.1111/j.1432-2277.2012.01512.x

Cillo, U., Bassanello, M., Vitale, A., Grigoletto, F. A., Burra, P., Fagiuoli, S., . . . D'Amico, D. F. (2004). The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol, 40(1), 124-131. 

Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanus, G., . . . D'Amico, D. F. (2006). Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol, 44(4), 723-731. doi:10.1016/j.jhep.2005.12.015

Cunningham, S. C., Tsai, S., Marques, H. P., Mira, P., Cameron, A., Barroso, E., . . . Pawlik, T. M. (2009). Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol, 16(7), 1820-1831. doi:10.1245/s10434-009-0364-1

D'Avola, D., Lnarrairaegui, M., Bilbao, J. I., Martinez-Cuesta, A., Alegre, F., Herrero, J. I., . . . Sangro, B. (2009). A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology, 56(96), 1683-1688. 

Dahiya, D., Wu, T. J., Lee, C. F., Chan, K. M., Lee, W. C., & Chen, M. F. (2010). Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery, 147(5), 676-685. doi:10.1016/j.surg.2009.10.043

Danielsson Borssen, A., Almer, S., Prytz, H., Wallerstedt, S., Friis-Liby, I. L., Bergquist, A., . . . Werner, M. (2015). Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol, 50(2), 217-223. doi:10.3109/00365521.2014.983154

Dart, R. C., Kuffner, E. K., & Rumack, B. H. (2000). Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther, 7(2), 123-134. 

De Luna, W., Sze, D. Y., Ahmed, A., Ha, B. Y., Ayoub, W., Keeffe, E. B., . . . Nguyen, M. H. (2009). Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant, 9(5), 1158-1168. doi:10.1111/j.1600-6143.2009.02576.x

Desmet, V. J. (2009). East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma. Hepatology, 49(2), 355-357. doi:10.1002/hep.22681

Dhanasekaran, R., Khanna, V., Kooby, D. A., Spivey, J. R., Parekh, S., Knechtle, S. J., . . . Kim, H. S. (2010). The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol, 21(8), 1197-1204; quiz 1204. doi:S1051-0443(10)00436-7 [pii]

10.1016/j.jvir.2010.04.018

Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., . . . Investigators, H.-C. T. (2008). Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med, 359(23), 2429-2441. doi:10.1056/NEJMoa0707615

Duberg, A.-S., Lybeck, C., Fält, A., Wedemeyer, H., Montgomery, S., & Aleman, S. (2018). The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden. Journal of Hepatology, 68(S48). 

Duncan, J. K., Ma, N., Vreugdenburg, T. D., Cameron, A. L., & Maddern, G. (2017). Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis. J Magn Reson Imaging, 45(1), 281-290. doi:10.1002/jmri.25345

Duvoux, C., Roudot-Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., . . . Liver Transplantation French Study, G. (2012). Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology, 143(4), 986-994 e983; quiz e914-985. doi:10.1053/j.gastro.2012.05.052

Ebara, M., Hatano, R., Fukuda, H., Yoshikawa, M., Sugiura, N., & Saisho, H. (1998). Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology, 45 Suppl 3, 1214-1220. 

Ebara, M., Ohto, M., Shinagawa, T., Sugiura, N., Kimura, K., Matsutani, S., . . . Okuda, K. (1986). Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology, 90(2), 289-298. 

Edeline, J., Crouzet, L., Campillo-Gimenez, B., Rolland, Y., Pracht, M., Guillygomarc'h, A., . . . Garin, E. (2016). Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging, 43(4), 635-643. doi:10.1007/s00259-015-3210-7

Edenvik, P., Davidsdottir, L., Oksanen, A., Isaksson, B., Hultcrantz, R., & Stal, P. (2015). Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int, 35(7), 1862-1871. doi:10.1111/liv.12764

Edmonds, K., Hull, D., Spencer-Shaw, A., Koldenhof, J., Chrysou, M., Boers-Doets, C., & Molassiotis, A. (2012). Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs, 16(2), 172-184. doi:10.1016/j.ejon.2011.05.001

Edmonsson, H., & Steiner, P. (1954). Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer, 462-503. 

Eguchi, S., Kanematsu, T., Arii, S., Okazaki, M., Okita, K., Omata, M., . . . Liver Cancer Study Group of, J. (2008). Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery, 143(4), 469-475. doi:10.1016/j.surg.2007.12.003

El-Gendi, A., El-Shafei, M., El-Gendi, S., & Shawky, A. (2018). Laparoscopic Versus Open Hepatic Resection for Solitary Hepatocellular Carcinoma Less Than 5 cm in Cirrhotic Patients: A Randomized Controlled Study. J Laparoendosc Adv Surg Tech A, 28(3), 302-310. doi:10.1089/lap.2017.0518

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., . . . Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 389(10088), 2492-2502. doi:10.1016/S0140-6736(17)31046-2

Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., . . . Askling, J. (2003). Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology, 125(6), 1733-1741. 

Elsayes, K. M., Hooker, J. C., Agrons, M. M., Kielar, A. Z., Tang, A., Fowler, K. J., . . . Sirlin, C. B. (2017). 2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics, 37(7), 1994-2017. doi:10.1148/rg.2017170098

Elzouki, A. N., & Eriksson, S. (1996). Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol, 8(10), 989-994. 

European Association for Study of, L. (2014). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 60(2), 392-420. doi:10.1016/j.jhep.2013.11.003

European Association For The Study Of The, L. (2010). EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol, 53(1), 3-22. doi:10.1016/j.jhep.2010.03.001

European Association For The Study Of The, L., European Organisation For, R., & Treatment Of, C. (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 56(4), 908-943. doi:10.1016/j.jhep.2011.12.001

European Association for the Study of the Liver. Electronic address, e. e. e., & European Association for the Study of the, L. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 67(2), 370-398. doi:10.1016/j.jhep.2017.03.021

European Association for the Study of the Liver. Electronic address, e. e. e., & European Association for the Study of the, L. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 69(1), 182-236. doi:10.1016/j.jhep.2018.03.019

European Union, H. C. V. C. (2017). Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol, 2(5), 325-336. doi:10.1016/S2468-1253(17)30045-6

Fan, S. T., Poon, R. T., Yeung, C., Lam, C. M., Lo, C. M., Yuen, W. K., . . . Chan, S. C. (2011). Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg, 98(9), 1292-1300. doi:10.1002/bjs.7583

Fan, S. Y., Eiser, C., & Ho, M. C. (2010). Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol, 8(7), 559-564 e551-510. doi:10.1016/j.cgh.2010.03.008

Fattovich, G., Bortolotti, F., & Donato, F. (2008). Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol, 48(2), 335-352. doi:10.1016/j.jhep.2007.11.011

Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., . . . Realdi, G. (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112(2), 463-472. 

Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127(5 Suppl 1), S35-50. 

Finn R, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim H-Y, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2019;37:4004-.

Flusberg, M., Ganeles, J., Ekinci, T., Goldberg-Stein, S., Paroder, V., Kobi, M., & Chernyak, V. (2017). Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis. J Am Coll Radiol, 14(9), 1206-1211. doi:10.1016/j.jacr.2017.02.050

Fong, Y., Sun, R. L., Jarnagin, W., & Blumgart, L. H. (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg, 229(6), 790-799; discussion 799-800. 

Forner, A., Llovet, J. M., & Bruix, J. (2012). Chemoembolization for intermediate HCC: is there proof of survival benefit? Journal of Hepatology, 56(4), 984-986. doi:10.1016/j.jhep.2011.08.017

Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. Lancet, 391(10127), 1301-1314. doi:10.1016/S0140-6736(18)30010-2

Fracanzani, A. L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A., & Fargion, S. (2001). Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology, 33(3), 647-651. doi:10.1053/jhep.2001.22506

Francica, G., Saviano, A., De Sio, I., De Matthaeis, N., Brunello, F., Cantamessa, A., . . . Pompili, M. (2013). Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis, 45(4), 336-341. doi:10.1016/j.dld.2012.10.022

Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., Carey, W., Practice Guidelines Committee of the American Association for the Study of Liver, D., & Practice Parameters Committee of the American College of, G. (2007). Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 46(3), 922-938. doi:10.1002/hep.21907

Gelatti, U., Covolo, L., Franceschini, M., Pirali, F., Tagger, A., Ribero, M. L., . . . Brescia, H. C. C. S. G. (2005). Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol, 42(4), 528-534. 

Giannini, E. G., Bodini, G., Corbo, M., Savarino, V., Risso, D., Di Nolfo, M. A., . . . Trevisani, F. (2010). Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther, 31(4), 493-501. doi:APT4198 [pii]

10.1111/j.1365-2036.2009.04198.x

Gisbert, J. P., Garcia-Buey, L., Alonso, A., Rubio, S., Hernandez, A., Pajares, J. M., . . . Moreno-Otero, R. (2004). Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol, 16(7), 689-692. 

Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J. F., . . . Thurston, K. (2005). Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol, 16(2 Pt 1), 205-213. doi:16/2/205 [pii]

10.1097/01.RVI.0000142592.89564.F9

Golfieri, R., Giampalma, E., Renzulli, M., Cioni, R., Bargellini, I., Bartolozzi, C., . . . Precision Italia Study, G. (2014). Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer, 111(2), 255-264. doi:10.1038/bjc.2014.199

Golfieri, R., Marini, E., Bazzocchi, A., Fusco, F., Trevisani, F., Sama, C., . . . Bolondi, L. (2009). Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. Radiol Med, 114(8), 1239-1266. doi:10.1007/s11547-009-0439-x

Golfieri, R., Mosconi, C., Cappelli, A., Giampalma, E., Galaverni, M. C., Pettinato, C., . . . Trevisani, F. (2015). Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. Future Oncol, 11(23), 3133-3142. doi:10.2217/fon.15.267

Gopal, P., Yopp, A. C., Waljee, A. K., Chiang, J., Nehra, M., Kandunoori, P., & Singal, A. G. (2014). Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol, 12(5), 870-877. doi:10.1016/j.cgh.2013.09.053

Gordic, S., Ayache, J. B., Kennedy, P., Besa, C., Wagner, M., Bane, O., . . . Taouli, B. (2017). Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. Abdom Radiol (NY), 42(6), 1685-1694. doi:10.1007/s00261-017-1066-y

Grat, M., Wronka, K. M., Stypulkowski, J., Bik, E., Krasnodebski, M., Masior, L., . . . Krawczyk, M. (2017). The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol, 24(2), 526-534. doi:10.1245/s10434-016-5500-0

Grazi, G. L., Ercolani, G., Pierangeli, F., Del Gaudio, M., Cescon, M., Cavallari, A., & Mazziotti, A. (2001). Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg, 234(1), 71-78. 

Grieco, A., Pompili, M., Caminiti, G., Miele, L., Covino, M., Alfei, B., . . . Gasbarrini, G. (2005). Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut, 54(3), 411-418. doi:10.1136/gut.2004.048124

Groenkjaer, L., Gasberg Andersen, N., Bolvig Hansen, L., Hoppe, T., Tholstrup Svensson, N., Elbæk Sømod, I., . . . Bager, P. (2016). Different views on hepatic encephalopathy: Patients, relatives and nurses (Vol. 14).

Grundmann, S., & Stander, S. (2011). Chronic pruritus: clinics and treatment. Ann Dermatol, 23(1), 1-11. doi:10.5021/ad.2011.23.1.1

Gruttadauria, S., & Pagano, D. (2018). Commentary on Cipriani et al.: Effect of Previous Abdominal Surgery on Laparoscopic Liver Resection: Analysis of Feasibility and Risk Factors for Conversion (J Laparoendosc Adv Surg Tech A 2018;28:785-791). J Laparoendosc Adv Surg Tech A, 28(7), 792-793. doi:10.1089/lap.2018.29024.sg

Gu, L., Liu, H., Fan, L., Lv, Y., Cui, Z., Luo, Y., . . . Ma, J. (2013). Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. Journal of cancer research and clinical oncology. doi:10.1007/s00432-013-1528-8

Gunn, A. J., Sheth, R. A., Luber, B., Huynh, M. H., Rachamreddy, N. R., & Kalva, S. P. (2017). Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria. Cardiovasc Intervent Radiol, 40(1), 61-68. doi:10.1007/s00270-016-1451-x

Guo, J., Seo, Y., Ren, S., Hong, S., Lee, D., Kim, S., & Jiang, Y. (2016). Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY), 41(10), 1960-1972. doi:10.1007/s00261-016-0807-7

Gurusamy, K. S., Pamecha, V., Sharma, D., & Davidson, B. R. (2009). Techniques for liver parenchymal transection in liver resection. Cochrane Database Syst Rev(1), CD006880. doi:10.1002/14651858.CD006880.pub2

Gustafsson, B., & Wiik, W. (2004). Bekräftande omvårdnad : SAUK-modellen för vård och omsorg. Lund: Studentlitteratur.

Gustafsson, B., & Willman, A. M. (2003). Nurses' self-relation--becoming theoretically competent: the SAUC model for confirming nursing. Nurs Sci Q, 16(3), 265-271. doi:10.1177/0894318403016003019

Hagstrom, H., Tynelius, P., & Rasmussen, F. (2018). High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut, 67(8), 1536-1542. doi:10.1136/gutjnl-2016-313622

Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., & Yao, F. Y. (2014). Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl, 20(8), 945-951. doi:10.1002/lt.23904

Hanna, R. F., Miloushev, V. Z., Tang, A., Finklestone, L. A., Brejt, S. Z., Sandhu, R. S., . . . Sirlin, C. B. (2016). Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY), 41(1), 71-90. doi:10.1007/s00261-015-0592-8

Hansen, L., Dieckmann, N. F., Kolbeck, K. J., Naugler, W. E., & Chang, M. F. (2017). Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life. Oncol Nurs Forum, 44(6), 665-673. doi:10.1188/17.Onf.665-673

Hansen, L., Rosenkranz, S. J., Vaccaro, G. M., & Chang, M. F. (2015). Patients With Hepatocellular Carcinoma Near the End of Life: A Longitudinal Qualitative Study of Their Illness Experiences. Cancer Nurs, 38(4), E19-27. doi:10.1097/ncc.0000000000000188

Hansen, L., Rosenkranz, S. J., Wherity, K., & Sasaki, A. (2017). Living With Hepatocellular Carcinoma Near the End of Life: Family Caregivers' Perspectives. Oncol Nurs Forum, 44(5), 562-570. doi:10.1188/17.Onf.562-570

Harimoto, N., Yoshizumi, T., Inokuchi, S., Itoh, S., Adachi, E., Ikeda, Y., . . . Maehara, Y. (2018). Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study. Ann Surg Oncol, 25(11), 3316-3323. doi:10.1245/s10434-018-6672-6

Harrison, S. A., & Bacon, B. R. (2005). Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am, 89(2), 391-409. doi:10.1016/j.mcna.2004.08.005

Hasegawa, K., Kokudo, N., Imamura, H., Matsuyama, Y., Aoki, T., Minagawa, M., . . . Makuuchi, M. (2005). Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg, 242(2), 252-259. 

Hassan, M. M., Hwang, L. Y., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., . . . Patt, Y. Z. (2002). Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36(5), 1206-1213. doi:10.1053/jhep.2002.36780

Hassan, M. M., Spitz, M. R., Thomas, M. B., Curley, S. A., Patt, Y. Z., Vauthey, J. N., . . . Li, D. (2009). The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol, 50(2), 334-341. doi:10.1016/j.jhep.2008.08.016

Heffernan, N., Cella, D., Webster, K., Odom, L., Martone, M., Passik, S., . . . Blumgart, L. (2002). Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol, 20(9), 2229-2239. doi:10.1200/jco.2002.07.093

Hegade, V. S., Bolier, R., Oude Elferink, R. P., Beuers, U., Kendrick, S., & Jones, D. E. (2016). A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol, 7(3), 158-166. doi:10.1136/flgastro-2015-100618

Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., . . . Marrero, J. A. (2018). AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 67(1), 358-380. doi:10.1002/hep.29086

Hoink, A. J., Schulke, C., Koch, R., Lohnert, A., Kammerer, S., Fortkamp, R., . . . Buerke, B. (2017). Response Evaluation of Malignant Liver Lesions After TACE/SIRT: Comparison of Manual and Semi-Automatic Measurement of Different Response Criteria in Multislice CT. Rofo, 189(11), 1067-1075. doi:10.1055/s-0043-116220

Hollinworth, H., & Mann, L. (2010). Managing acute skin reactions to radiotherapy treatment. Nurs Stand, 24(24), 53-54, 56, 58 passim. doi:10.7748/ns2010.02.24.24.53.c7558

Holt, A., Wagman, L. D., Senthil, M., McKenzie, S., Marx, H., Chen, Y. J., . . . Kim, J. (2010). Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center. The American surgeon, 76(10), 1079-1083. 

Houben, K. W., & McCall, J. L. (1999). Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg, 5(2), 91-95. doi:10.1002/lt.500050201

Hu, Y., Liu, T., & Li, F. (2019). Association between dyadic interventions and outcomes in cancer patients: a meta-analysis. Support Care Cancer, 27(3), 745-761. doi:10.1007/s00520-018-4556-8

Inarrairaegui, M., Martinez-Cuesta, A., Rodriguez, M., Bilbao, J. I., Arbizu, J., Benito, A., . . . Sangro, B. (2010). Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 77(5), 1441-1448. doi:S0360-3016(09)01033-5 [pii]

10.1016/j.ijrobp.2009.07.006

Innala, E., & Andersson, C. (2011). Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med, 269(5), 538-545. doi:10.1111/j.1365-2796.2010.02335.x

Inoue, M., Yoshimi, I., Sobue, T., Tsugane, S., & Group, J. S. (2005). Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst, 97(4), 293-300. doi:10.1093/jnci/dji040

Ioannou, G. N., Green, P. K., Beste, L. A., Mun, E. J., Kerr, K. F., & Berry, K. (2018). Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol, 69(5), 1088-1098. doi:10.1016/j.jhep.2018.07.024

Ip, H. M., Lelie, P. N., Wong, V. C., Kuhns, M. C., & Reesink, H. W. (1989). Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet, 1(8635), 406-410. 

Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., . . . et al. (1995). Histological grading and staging of chronic hepatitis. J Hepatol, 22(6), 696-699. 

Jang, J. W., You, C. R., Kim, C. W., Bae, S. H., Yoon, S. K., Yoo, Y. K., . . . Choi, J. Y. (2010). Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther, 31(3), 415-423. doi:10.1111/j.1365-2036.2009.04167.x

Jean-Pierre, P., Morrow, G. R., Roscoe, J. A., Heckler, C., Mohile, S., Janelsins, M., . . . Hopkins, J. O. (2010). A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer, 116(14), 3513-3520. doi:10.1002/cncr.25083

Jepsen, P., Ott, P., Andersen, P. K., Sorensen, H. T., & Vilstrup, H. (2012). Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med, 156(12), 841-847, W295. doi:10.7326/0003-4819-156-12-201206190-00004

Jones, E. A., Molenaar, H. A., & Oosting, J. (2007). Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology, 54(76), 1196-1199. 

Kaberg, M., Naver, G., Hammarberg, A., & Weiland, O. (2018). Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. J Viral Hepat, 25(12), 1452-1461. doi:10.1111/jvh.12969

Kaczynski, J., Hansson, G., & Wallerstedt, S. (1995). Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. An autopsy study from a low endemic area. Acta Oncol, 34(1), 43-48. 

Kaczynski, J., Hansson, G., & Wallerstedt, S. (2005). Clinical features in hepatocellular carcinoma and the impact of autopsy on diagnosis. A study of 530 cases from a low-endemicity area. Hepatogastroenterology, 52(66), 1798-1802. 

Kaczynski, J., Hansson, G., & Wallerstedt, S. (2006). Diabetes: one of few remarkable differences in clinicopathologic features between cirrhotic and noncirrhotic Swedes with hepatocellular carcinoma. Dig Dis Sci, 51(4), 796-802. doi:10.1007/s10620-006-3209-9

Kahn, C. E., Jr., Heilbrun, M. E., & Applegate, K. E. (2013). From guidelines to practice: how reporting templates promote the use of radiology practice guidelines. J Am Coll Radiol, 10(4), 268-273. doi:10.1016/j.jacr.2012.09.025

Kamath, A., Roudenko, A., Hecht, E., Sirlin, C., Chernyak, V., Fowler, K., & Mitchell, D. G. (2019). CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY). doi:10.1007/s00261-018-1868-6

Kambadakone, A. R., Fung, A., Gupta, R. T., Hope, T. A., Fowler, K. J., Lyshchik, A., . . . Miller, F. H. (2018). LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY), 43(1), 56-74. doi:10.1007/s00261-017-1325-y

Karim, K. (2011). Diagnosis, treatment and management of pruritus. Br J Nurs, 20(6), 356-361. doi:10.12968/bjon.2011.20.6.356

Katsagoni, C. N., Georgoulis, M., Papatheodoridis, G. V., Panagiotakos, D. B., & Kontogianni, M. D. (2017). Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism, 68, 119-132. doi:10.1016/j.metabol.2016.12.006

Keulers, B. J., Scheltinga, M. R., Houterman, S., Van Der Wilt, G. J., & Spauwen, P. H. (2008). Surgeons underestimate their patients' desire for preoperative information. World J Surg, 32(6), 964-970. doi:10.1007/s00268-008-9581-1

Kew, M. C. (2014). Hepatic iron overload and hepatocellular carcinoma. Liver Cancer, 3(1), 31-40. doi:10.1159/000343856

Kew, M. C., Hodkinson, J., Paterson, A. C., & Song, E. (1982). Hepatitis-B virus infection in black children with hepatocellular carcinoma. J Med Virol, 9(3), 201-207. 

Khalili, K., Kim, T. K., Jang, H. J., Yazdi, L. K., Guindi, M., & Sherman, M. (2011). Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology, 54(6), 2048-2054. doi:10.1002/hep.24638

Kim, D. Y., & Han, K. H. (2016). Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int, 10(6), 883-892. doi:10.1007/s12072-016-9722-9

Kim, G. A., Seock, C. H., Park, J. W., An, J., Lee, K. S., Yang, J. E., . . . Lee, H. C. (2015). Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int, 35(1), 232-239. doi:10.1111/liv.12516

Kim, J. H., Kim, Y. D., Lee, M., Jun, B. G., Kim, T. S., Suk, K. T., . . . Choi, D. H. (2018). Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol, 69(5), 1066-1073. doi:10.1016/j.jhep.2018.07.018

Kim, J. H., Shim, J. H., Lee, H. C., Sung, K. B., Ko, H. K., Ko, G. Y., . . . Park, S. H. (2017). New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int, 37(12), 1861-1868. doi:10.1111/liv.13487

Kim, J. H., Shim, J. H., Yoon, H. K., Ko, H. K., Kim, J. W., & Gwon, D. I. (2018). Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int, 38(9), 1646-1654. doi:10.1111/liv.13719

Kim, S. H., Choi, B. I., Lee, J. Y., Kim, S. J., So, Y. H., Eun, H. W., . . . Han, J. K. (2008). Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the milan criteria before liver transplantation. Intervirology, 51 Suppl 1, 52-60. doi:10.1159/000122598

Kim, S. H., Lim, H. K., Lee, W. J., Cho, J. M., & Jang, H. J. (2000). Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging, 25(3), 246-250. 

Kirchhoff, T. D., Rudolph, K. L., Layer, G., Chavan, A., Greten, T. F., Rosenthal, H., . . . Gallkowski, U. (2006). Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol, 32(2), 201-207. doi:S0748-7983(05)00320-3 [pii]

10.1016/j.ejso.2005.11.003

Klompenhouwer, E. G., Dresen, R. C., Verslype, C., Laenen, A., Bonne, L., Vandecaveye, V., & Maleux, G. (2018). Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival. Cardiovasc Intervent Radiol, 41(11), 1716-1726. doi:10.1007/s00270-018-1991-3

Kolligs, F. T., Bilbao, J. I., Jakobs, T., Inarrairaegui, M., Nagel, J. M., Rodriguez, M., . . . Sangro, B. (2015). Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int, 35(6), 1715-1721. doi:10.1111/liv.12750

Kooby, D. A., Egnatashvili, V., Srinivasan, S., Chamsuddin, A., Delman, K. A., Kauh, J., . . . Kim, H. S. (2010). Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol, 21(2), 224-230. doi:S1051-0443(09)01049-5 [pii]

10.1016/j.jvir.2009.10.013

Kornberg, A., Witt, U., Kornberg, J., Ceyhan, G. O., Mueller, K., Friess, H., & Thrum, K. (2016). Prognostic Impact of Intraoperative Blood Loss in Liver Transplant Patients with Advanced Hepatocellular Carcinoma. Anticancer Res, 36(10), 5355-5364. doi:10.21873/anticanres.11109

Kouwenhoven, T. A., van de Kerkhof, P. C. M., & Kamsteeg, M. (2017). Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol, 77(6), 1068-1073.e1067. doi:10.1016/j.jaad.2017.08.025

Koya, S., Kawaguchi, T., Hashida, R., Goto, E., Matsuse, H., Saito, H., . . . Torimura, T. (2017). Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease. Hepatol Res, 47(3), E22-e34. doi:10.1111/hepr.12718

Koya, S., Kawaguchi, T., Hashida, R., Hirota, K., Bekki, M., Goto, E., . . . Torimura, T. (2019). Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. J Gastroenterol Hepatol, 34(3), 580-588. doi:10.1111/jgh.14538

Kuang, M., Xie, X. Y., Huang, C., Wang, Y., Lin, M. X., Xu, Z. F., . . . Lu, M. D. (2011). Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg, 15(12), 2165-2171. doi:10.1007/s11605-011-1716-2

Kubota, K., Ina, H., Okada, Y., & Irie, T. (2003). Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci, 48(3), 581-586. 

Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., . . . Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391(10126), 1163-1173. doi:10.1016/S0140-6736(18)30207-1

Kulik, L., Heimbach, J. K., Zaiem, F., Almasri, J., Prokop, L. J., Wang, Z., . . . Mohammed, K. (2018). Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology, 67(1), 381-400. doi:10.1002/hep.29485

Kulik, L. M., Atassi, B., van Holsbeeck, L., Souman, T., Lewandowski, R. J., Mulcahy, M. F., . . . Salem, R. (2006). Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol, 94(7), 572-586. doi:10.1002/jso.20609

Kwon, J. H., Bae, S. H., Kim, J. Y., Choi, B. O., Jang, H. S., Jang, J. W., . . . Chung, K. W. (2010). Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer, 10, 475. doi:10.1186/1471-2407-10-475

Lagging, L. M., Aneman, C., Nenonen, N., Brandberg, A., Grip, L., Norkrans, G., & Lindh, M. (2002). Nosocomial transmission of HCV in a cardiology ward during the window phase of infection: an epidemiological and molecular investigation. Scand J Infect Dis, 34(8), 580-582. doi:10.1080/00365540110080926

Lai, Q., Avolio, A. W., Graziadei, I., Otto, G., Rossi, M., Tisone, G., . . . Lerut, J. (2013). Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl, 19(10), 1108-1118. doi:10.1002/lt.23706

Lam, A., Fernando, D., Sirlin, C. C., Nayyar, M., Goodwin, S. C., Imagawa, D. K., & Lall, C. (2017). Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation. Clin Radiol, 72(11), 994.e999-994.e916. doi:10.1016/j.crad.2017.07.003

Lam, W., Wong, F. Y., & Chan, A. E. (2018). Factors Affecting the Levels of Satisfaction With Nurse-Patient Communication Among Oncology Patients. Cancer Nurs. doi:10.1097/ncc.0000000000000672

Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., . . . Lencioni, R. (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 33(1), 41-52. doi:10.1007/s00270-009-9711-7

Lance, C., McLennan, G., Obuchowski, N., Cheah, G., Levitin, A., Sands, M., . . . Menon, K. V. (2011). Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. Journal of vascular and interventional radiology : JVIR, 22(12), 1697-1705. doi:10.1016/j.jvir.2011.08.013

Larsson, S. C., & Wolk, A. (2007). Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer, 97(7), 1005-1008. doi:10.1038/sj.bjc.6603932

Le Treut, Y. P., Hardwigsen, J., Ananian, P., Saisse, J., Gregoire, E., Richa, H., & Campan, P. (2006). Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg, 10(6), 855-862. doi:10.1016/j.gassur.2005.12.011

Lee, D., Lee, H. C., An, J., Shim, J. H., Kim, K. M., Lim, Y. S., . . . Lee, Y. S. (2018). Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. Clin Mol Hepatol, 24(2), 144-150. doi:10.3350/cmh.2017.0041

Lee, D. H., Kim, S. H., Lee, J. M., Park, H. S., Lee, J. Y., Yi, N. J., . . . Choi, B. I. (2009). Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol, 44(6), 311-321. 

Lee, E., Edward, S., Singal, A. G., Lavieri, M. S., & Volk, M. (2013). Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 11(4), 437-440. doi:10.1016/j.cgh.2012.11.029

Lee, H. H., Chiu, C. C., Lin, J. J., Wang, J. J., Lee, K. T., Sun, D. P., & Shi, H. Y. (2019). Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord, 246, 361-367. doi:10.1016/j.jad.2018.12.085

Lee, J. M., Jang, B. K., Lee, Y. J., Choi, W. Y., Choi, S. M., Chung, W. J., . . . Lee, C. H. (2016). Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol, 22(1), 160-167. doi:10.3350/cmh.2016.22.1.160

Lee, S. W., Lee, H. L., Han, N. I., Kwon, J. H., Nam, S. W., Jang, J. W., . . . Yoon, S. K. (2017). Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol, 9(10), 615-626. doi:10.1177/1758834017728018

Lee, Y. J., Lee, J. M., Lee, J. S., Lee, H. Y., Park, B. H., Kim, Y. H., . . . Choi, B. I. (2015). Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology, 275(1), 97-109. doi:10.1148/radiol.14140690

Lencioni, R., Crocetti, L., Della Pina, M. C., & Cioni, D. (2008). Guidelines for imaging focal lesions in liver cirrhosis. Expert Rev Gastroenterol Hepatol, 2(5), 697-703. doi:10.1586/17474124.2.5.697

Lencioni, R., Piscaglia, F., & Bolondi, L. (2008). Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol, 48(5), 848-857. doi:10.1016/j.jhep.2008.02.005

Leng, J. J., Xu, Y. Z., & Dong, J. H. (2016). Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg, 86(10), 816-820. doi:10.1111/ans.12803

Leoni, S., Piscaglia, F., Golfieri, R., Camaggi, V., Vidili, G., Pini, P., & Bolondi, L. (2010). The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol, 105(3), 599-609. doi:10.1038/ajg.2009.654

Lewandowski, R. J., Kulik, L. M., Riaz, A., Senthilnathan, S., Mulcahy, M. F., Ryu, R. K., . . . Salem, R. (2009). A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 9(8), 1920-1928. doi:AJT2695 [pii]

10.1111/j.1600-6143.2009.02695.x

Levrero, M., & Zucman-Rossi, J. (2016). Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol, 64(1 Suppl), S84-S101. doi:10.1016/j.jhep.2016.02.021

Li, M. F., Leung, H. W., Chan, A. L., & Wang, S. Y. (2018). Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag, 14, 1157-1168. doi:10.2147/tcrm.S162898

Li, W., Li, L., Han, J., & Wu, H. (2018). Liver transplantation vs liver resection in patients with HBV-related hepatocellular carcinoma beyond Milan criterion: A meta-analysis. Clin Transplant, 32(3), e13193. doi:10.1111/ctr.13193

Liang, H., Cui, P., Guo, Q., Mao, X., Wen, F., Sun, W., . . . Lu, Z. (2017). Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol, 13(5), e331-e341. doi:10.1111/ajco.12606

Liao, M., Huang, J., Zhang, T., & Wu, H. (2013). Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PloS one, 8(7), e68453. doi:10.1371/journal.pone.0068453

Libbrecht, L., Desmet, V., & Roskams, T. (2005). Preneoplastic lesions in human hepatocarcinogenesis. Liver Int, 25(1), 16-27. doi:10.1111/j.1478-3231.2005.01016.x

Lim, H. W., & Mascaro, J. M. (1995). The porphyrias and hepatocellular carcinoma. Dermatol Clin, 13(1), 135-142. 

Lim, S. G., Mohammed, R., Yuen, M. F., & Kao, J. H. (2009). Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol, 24(8), 1352-1357. doi:10.1111/j.1440-1746.2009.05985.x

Lin, C. L., & Kao, J. H. (2013). Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol, 28(1), 10-17. doi:10.1111/jgh.12010

Lindh, M., Uhnoo, I., Blackberg, J., Duberg, A. S., Friman, S., Fischler, B., . . . Wistrom, J. (2008). Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scand J Infect Dis, 40(6-7), 436-450. doi:10.1080/00365540802154769

Lithner, M., & Zilling, T. (1998). Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). . In Vård i Norden (pp. 31-33, 39).

Liu, L., Zhang, C., Zhao, Y., Qi, X., Chen, H., Bai, W., . . . Han, G. (2014). Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int, 2014, 194278. doi:10.1155/2014/194278

Liu, W., Qin, J., Guo, R., Xie, S., Jiang, H., Wang, X., . . . Shan, H. (2018). Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS. Acta Radiol, 59(2), 140-146. doi:10.1177/0284185117716700

Liver., E. A. f. t. S. o. t. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 69(1), 182-236. doi:10.1016/j.jhep.2018.03.019

Llovet, J. M., & Bruix, J. (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48(4), 1312-1327. doi:10.1002/hep.22506

Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 30(6), 1434-1440. doi:10.1002/hep.510300629

Llovet, J. M., Real, M. I., Montana, X., Planas, R., Coll, S., Aponte, J., . . . Bruix, J. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359(9319), 1734-1739. doi:S0140-6736(02)08649-X [pii]

10.1016/S0140-6736(02)08649-X

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., . . . Group, S. I. S. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359(4), 378-390. doi:10.1056/NEJMoa0708857

Lo, C. M., Ngan, H., Tso, W. K., Liu, C. L., Lam, C. M., Poon, R. T., . . . Wong, J. (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35(5), 1164-1171. doi:S0270913902877138 [pii]

10.1053/jhep.2002.33156

Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., . . . Group, H.-C. T. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136(1), 138-148. doi:10.1053/j.gastro.2008.09.014

Lok, A. S., Sterling, R. K., Everhart, J. E., Wright, E. C., Hoefs, J. C., Di Bisceglie, A. M., . . . Group, H.-C. T. (2010). Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 138(2), 493-502. doi:10.1053/j.gastro.2009.10.031

Long, J., Zheng, J. S., Sun, B., & Lu, N. (2016). Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int, 10(1), 175-184. doi:10.1007/s12072-015-9673-6

Lopez, P. M., Villanueva, A., Roayaie, S., & Llovet, J. M. (2006). Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl, 12(12), 1747-1754. doi:10.1002/lt.21018

Loughney, L. A., West, M. A., Kemp, G. J., Grocott, M. P., & Jack, S. (2018). Exercise interventions for people undergoing multimodal cancer treatment that includes surgery. Cochrane Database Syst Rev, 12, Cd012280. doi:10.1002/14651858.CD012280.pub2

Louha, M., Nicolet, J., Zylberberg, H., Sabile, A., Vons, C., Vona, G., . . . Paterlini-Brechot, P. (1999). Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology, 29(3), 879-882. doi:10.1002/hep.510290348

Lu, W., Li, Y. H., He, X. F., Mo, Y. Y., & Zhu, Z. Y. (2011). Transcatheter arterial chemoembolization enhances expression of Nm23-H1 and TIMP-2 in the tumor tissue of patients with hepatocellular carcinoma. Hepato-gastroenterology, 58(106), 558-564. 

Lu, W., Li, Y. H., He, X. F., Zhao, J. B., Chen, Y., & Mei, Q. L. (2008). Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol, 31(6), 1133-1140. doi:10.1007/s00270-008-9379-4

Lundstrom, S. H., & Furst, C. J. (2006). The use of corticosteroids in Swedish palliative care. Acta Oncol, 45(4), 430-437. doi:10.1080/02841860500401167

Läkemedelsbehandling av hepatit C-virusinfektion hos vuxna och barn. (2017). Referensgruppen för Antiviral Terapi (RAV). .

Mabed, M., Esmaeel, M., El-Khodary, T., Awad, M., & Amer, T. (2009). A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl), 18(5), 492-499. doi:ECC984 [pii]

10.1111/j.1365-2354.2008.00984.x

Maddala, Y. K., Stadheim, L., Andrews, J. C., Burgart, L. J., Rosen, C. B., Kremers, W. K., & Gores, G. (2004). Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl, 10(3), 449-455. doi:10.1002/lt.20099

Majno, P., Lencioni, R., Mornex, F., Girard, N., Poon, R. T., & Cherqui, D. (2011). Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl, 17 Suppl 2, S98-108. doi:10.1002/lt.22391

Malagari, K., Pomoni, M., Moschouris, H., Bouma, E., Koskinas, J., Stefaniotou, A., . . . Kelekis, D. (2012). Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol, 35(5), 1119-1128. doi:10.1007/s00270-012-0394-0

Manchen, E., Robert, C., & Porta, C. (2011). Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol, 9(1), 13-23. 

Mansour-Ghanaei, F., Taheri, A., Froutan, H., Ghofrani, H., Nasiri-Toosi, M., Bagherzadeh, A. H., . . . Pourrasouli, Z. (2006). Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol, 12(7), 1125-1128. 

Marin-Hargreaves, G., Azoulay, D., & Bismuth, H. (2003). Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol, 47(1), 13-27. 

Marin Caro, M. M., Laviano, A., & Pichard, C. (2007). Nutritional intervention and quality of life in adult oncology patients. Clin Nutr, 26(3), 289-301. doi:10.1016/j.clnu.2007.01.005

Marin, H. L., Furth, E. E., Olthoff, K., Shaked, A., & Soulen, M. C. (2009). Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma. J Gastrointestin Liver Dis, 18(2), 169-176. 

Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., . . . Schwartz, M. (2009). Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137(1), 110-118. doi:10.1053/j.gastro.2009.04.005

Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology, 41(4), 707-716. doi:10.1002/hep.20636

Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., . . . Heimbach, J. K. (2018). Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68(2), 723-750. doi:10.1002/hep.29913

Masuzaki, R., Karp, S. J., & Omata, M. (2012). New serum markers of hepatocellular carcinoma. Semin Oncol, 39(4), 434-439. doi:10.1053/j.seminoncol.2012.05.009

Matsui, O., Kobayashi, S., Sanada, J., Kouda, W., Ryu, Y., Kozaka, K., . . . Gabata, T. (2011). Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging, 36(3), 264-272. doi:10.1007/s00261-011-9685-1

Matsui, Y., Horikawa, M., Jahangiri Noudeh, Y., Kaufman, J. A., Kolbeck, K. J., & Farsad, K. (2017). Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence. Radiol Oncol, 51(4), 393-400. doi:10.1515/raon-2017-0030

Mazzaferro, V., Battiston, C., Perrone, S., Pulvirenti, A., Regalia, E., Romito, R., . . . Andreola, S. (2004). Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg, 240(5), 900-909. 

Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., . . . Majno, P. (2009). Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 10(1), 35-43. doi:S1470-2045(08)70284-5 [pii]

10.1016/S1470-2045(08)70284-5

Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., . . . Gennari, L. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 334(11), 693-699. doi:10.1056/NEJM199603143341104

Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., . . . Cucchetti, A. (2018). Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 154(1), 128-139. doi:10.1053/j.gastro.2017.09.025

McGlynn, K. A., Petrick, J. L., & London, W. T. (2015). Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis, 19(2), 223-238. doi:10.1016/j.cld.2015.01.001

McMullen, L. (2013). Oncology nurse navigators and the continuum of cancer care. Semin Oncol Nurs, 29(2), 105-117. doi:10.1016/j.soncn.2013.02.005

Mehta, N., Dodge, J. L., Roberts, J. P., Hirose, R., & Yao, F. Y. (2019). Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology, 69(3), 1193-1205. doi:10.1002/hep.30413

Mikoshiba, N., Miyashita, M., Sakai, T., Tateishi, R., & Koike, K. (2013). Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life. Psychooncology, 22(10), 2347-2353. doi:10.1002/pon.3300

Mitchell, D. G., Bashir, M. R., & Sirlin, C. B. (2018). Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations. Abdom Radiol (NY), 43(1), 143-148. doi:10.1007/s00261-017-1251-z

Mittal, S., & El-Serag, H. B. (2013). Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol, 47 Suppl, S2-6. doi:10.1097/MCG.0b013e3182872f29

Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., . . . Davila, J. A. (2016). Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol, 14(1), 124-131 e121. doi:10.1016/j.cgh.2015.07.019

Mohandas, H., Jaganathan, S. K., Mani, M. P., Ayyar, M., & Rohini Thevi, G. V. (2017). Cancer-related fatigue treatment: An overview. J Cancer Res Ther, 13(6), 916-929. doi:10.4103/jcrt.JCRT_50_17

Moreno-Luna, L. E., Yang, J. D., Sanchez, W., Paz-Fumagalli, R., Harnois, D. M., Mettler, T. A., . . . Roberts, L. R. (2013). Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovascular and interventional radiology, 36(3), 714-723. doi:10.1007/s00270-012-0481-2

Mudumbi, S. K., Bourgeois, C. E., Hoppman, N. A., Smith, C. H., Verma, M., Bakitas, M. A., . . . Markland, A. D. (2018). Palliative Care and Hospice Interventions in Decompensated Cirrhosis and Hepatocellular Carcinoma: A Rapid Review of Literature. J Palliat Med, 21(8), 1177-1184. doi:10.1089/jpm.2017.0656

Muller, C., Pongratz, S., Pidlich, J., Penner, E., Kaider, A., Schemper, M., . . . Ferenci, P. (1998). Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol, 10(10), 865-870. 

Murali, A. R., Romero-Marrero, C., Miller, C., Aucejo, F., Levitin, A., Gill, A., . . . Menon, K. V. (2016). Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria. Transplantation, 100(11), 2391-2397. doi:10.1097/tp.0000000000001402

Nakagomi, R., Tateishi, R., Masuzaki, R., Soroida, Y., Iwai, T., Kondo, M., . . . Koike, K. (2018). Liver stiffness measurements in chronic hepatitis C: treatment evaluation and risk assessment. J Gastroenterol Hepatol. doi:10.1111/jgh.14530

Nanashima, A., Sumida, Y., Abo, T., Takeshita, H., Hidaka, S., Sawai, T., . . . Nagayasu, T. (2009). Trisectionectomy for large hepatocellular carcinoma using the liver hanging maneuver. Eur J Surg Oncol, 35(3), 326-330. doi:10.1016/j.ejso.2008.01.023

Nguyen, V. T., Law, M. G., & Dore, G. J. (2009). Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat, 16(7), 453-463. doi:10.1111/j.1365-2893.2009.01117.x

NLTR, Nordic Liver Transplant Registry. www.scandiatransplant.org/organ-allocation. 

Okada, S., Shimada, K., Yamamoto, J., Takayama, T., Kosuge, T., Yamasaki, S., . . . Hirohashi, S. (1994). Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology, 106(6), 1618-1624. 

Okazaki, N., Yoshino, M., Yoshida, T., Suzuki, M., Moriyama, N., Takayasu, K., . . . et al. (1989). Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer, 63(11), 2207-2210. 

Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., . . . Ohnishi, K. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56(4), 918-928. 

Okusaka, T., Kasugai, H., Shioyama, Y., Tanaka, K., Kudo, M., Saisho, H., . . . Sato, T. (2009). Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol, 51(6), 1030-1036. doi:S0168-8278(09)00588-1 [pii]

10.1016/j.jhep.2009.09.004

Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011). Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. The Cochrane database of systematic reviews(3), CD004787. doi:10.1002/14651858.CD004787.pub2

Ozkan, Z. G., Poyanli, A., Ucar, A., Kuyumcu, S., Akyuz, F., Keskin, S., . . . Turkmen, C. (2015). Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biother Radiopharm, 30(3), 132-138. doi:10.1089/cbr.2014.1748

Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., . . . Lampertico, P. (2016). PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol, 64(4), 800-806. doi:10.1016/j.jhep.2015.11.035

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. (2009). Hepatology, 49(2), 658-664. doi:10.1002/hep.22709

Peng, Z. W., Zhang, Y. J., Liang, H. H., Lin, X. J., Guo, R. P., & Chen, M. S. (2012). Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology, 262(2), 689-700. doi:10.1148/radiol.11110637

Perney, P., Segalas, F., Nalpas, B., Chanques, G., Rigole, H., Duny, Y., . . . Pageaux, G. P. (2013). Impact of tobacco and alcohol consumption in patients registered on waiting list on early morbidity following liver transplantation. Clin Res Hepatol Gastroenterol, 37(5), 473-478. doi:10.1016/j.clinre.2013.01.009

Pinna, A. D., Yang, T., Mazzaferro, V., De Carlis, L., Zhou, J., Roayaie, S., . . . Cucchetti, A. (2018). Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Ann Surg, 268(5), 868-875. doi:10.1097/sla.0000000000002889

Piorkowsky, N. Y. (2009). Europe's hepatitis challenge: defusing the "viral time bomb". J Hepatol, 51(6), 1068-1073. doi:10.1016/j.jhep.2009.09.010

Pitton, M. B., Kloeckner, R., Ruckes, C., Wirth, G. M., Eichhorn, W., Worns, M. A., . . . Dueber, C. (2015). Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 38(2), 352-360. doi:10.1007/s00270-014-1012-0

Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., . . . Hickman, M. (2017). Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev, 9, CD012021. doi:10.1002/14651858.CD012021.pub2

Plessier, A., Codes, L., Consigny, Y., Sommacale, D., Dondero, F., Cortes, A., . . . Durand, F. (2004). Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl, 10(2 Suppl 1), S86-90. doi:10.1002/lt.20039

Pocha, C., Dieperink, E., McMaken, K. A., Knott, A., Thuras, P., & Ho, S. B. (2013). Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther, 38(3), 303-312. doi:10.1111/apt.12370

Polaris Observatory, C. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 3(6), 383-403. doi:10.1016/S2468-1253(18)30056-6

Pomfret, E. A., Washburn, K., Wald, C., Nalesnik, M. A., Douglas, D., Russo, M., . . . Lake, J. (2010). Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl, 16(3), 262-278. doi:10.1002/lt.21999

Pommergaard, H. C., Rostved, A. A., Adam, R., Thygesen, L. C., Salizzoni, M., Gomez Bravo, M. A., . . . Rasmussen, A. (2018). Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int, 31(5), 531-539. doi:10.1111/tri.13123

Pons, F., Varela, M., & Llovet, J. M. (2005). Staging systems in hepatocellular carcinoma. HPB (Oxford), 7(1), 35-41. doi:10.1080/13651820410024058

Poon, R. T., & Fan, S. T. (2004). Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl, 10(2 Suppl 1), S39-45. doi:10.1002/lt.20040

Poon, R. T., & Fan, S. T. (2005). Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg, 12(1), 31-37. doi:10.1007/s00534-004-0945-0

Poon, R. T., Fan, S. T., O'Suilleabhain, C. B., & Wong, J. (2002). Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg, 195(3), 311-318. doi:S1072-7515(02)01226-7 [pii]

Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Kuriyakose, S., Leyssen, M., & Jacquet, J. M. (2011). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat, 18(5), 369-375. doi:10.1111/j.1365-2893.2010.01312.x

Porrett, P. M., Peterman, H., Rosen, M., Sonnad, S., Soulen, M., Markmann, J. F., . . . Olthoff, K. (2006). Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl, 12(4), 665-673. doi:10.1002/lt.20636

Raoul, J. L., Kudo, M., Finn, R. S., Edeline, J., Reig, M., & Galle, P. R. (2018). Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev, 68, 16-24. doi:10.1016/j.ctrv.2018.05.006

Regimbeau, J. M., Kianmanesh, R., Farges, O., Dondero, F., Sauvanet, A., & Belghiti, J. (2002). Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery, 131(3), 311-317. 

Rehm, J., Taylor, B., Mohapatra, S., Irving, H., Baliunas, D., Patra, J., & Roerecke, M. (2010). Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev, 29(4), 437-445. doi:10.1111/j.1465-3362.2009.00153.x

Rim, C. H., Kim, C. Y., Yang, D. S., & Yoon, W. S. (2018). Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol, 129(1), 112-122. doi:10.1016/j.radonc.2017.11.013

Ronot, M., Fouque, O., Esvan, M., Lebigot, J., Aube, C., & Vilgrain, V. (2017). Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol. doi:10.1016/j.jhep.2017.12.014

Roskams, T. (2006). Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene, 25(27), 3818-3822. doi:10.1038/sj.onc.1209558

Salata, H., Cortes, J. M., Enriquez de Salamanca, R., Oliva, H., Castro, A., Kusak, E., . . . Hernandez Guio, C. (1985). Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol, 1(5), 477-487. 

Salem, R., Lewandowski, R. J., Atassi, B., Gordon, S. C., Gates, V. L., Barakat, O., . . . Thurston, K. G. (2005). Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol, 16(12), 1627-1639. doi:16/12/1627 [pii]

10.1097/01.RVI.0000184594.01661.81

Salem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., . . . Mulcahy, M. F. (2011). Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology, 140(2), 497-507 e492. doi:10.1053/j.gastro.2010.10.049

Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., . . . Kulik, L. (2010). Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology, 138(1), 52-64. doi:10.1053/j.gastro.2009.09.006

Sangiovanni, A., & Colombo, M. (2011). Surveillance for hepatocellular carcinoma: a standard of care, not a clinical option. Hepatology, 54(6), 1898-1900. doi:10.1002/hep.24684

Sangiovanni, A., Manini, M. A., Iavarone, M., Romeo, R., Forzenigo, L. V., Fraquelli, M., . . . Colombo, M. (2010). The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut, 59(5), 638-644. doi:10.1136/gut.2009.187286

Sangro, B., Bilbao, J. I., Boan, J., Martinez-Cuesta, A., Benito, A., Rodriguez, J., . . . Prieto, J. (2006). Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 66(3), 792-800. doi:S0360-3016(06)00958-8 [pii]

10.1016/j.ijrobp.2006.05.065

Santagostino, E., Colombo, M., Rivi, M., Rumi, M. G., Rocino, A., Linari, S., . . . Study Group of the Association of Italian Hemophilia, C. (2003). A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood, 102(1), 78-82. doi:10.1182/blood-2002-10-3310

Santi, V., Trevisani, F., Gramenzi, A., Grignaschi, A., Mirici-Cappa, F., Del Poggio, P., . . . Italian Liver Cancer, G. (2010). Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol, 53(2), 291-297. doi:10.1016/j.jhep.2010.03.010

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., . . . Robuck, P. R. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 362(18), 1675-1685. doi:10.1056/NEJMoa0907929

Sarasin, F. P., Giostra, E., & Hadengue, A. (1996). Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med, 101(4), 422-434. doi:10.1016/S0002-9343(96)00197-0

Sardh, E., Wahlin, S., Bjornstedt, M., Harper, P., & Andersson, D. E. (2013). High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria. J Inherit Metab Dis, 36(6), 1063-1071. doi:10.1007/s10545-012-9576-9

Schoniger-Hekele, M., Muller, C., Kutilek, M., Oesterreicher, C., Ferenci, P., & Gangl, A. (2000). Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol, 12(8), 941-948. 

Setiawan, V. W., Wilkens, L. R., Lu, S. C., Hernandez, B. Y., Le Marchand, L., & Henderson, B. E. (2015). Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology, 148(1), 118-125; quiz e115. doi:10.1053/j.gastro.2014.10.005

Sharma, S. A., Kowgier, M., Hansen, B. E., Brouwer, W. P., Maan, R., Wong, D., . . . Feld, J. J. (2017). Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. doi:10.1016/j.jhep.2017.07.033

Shi, M., Guo, R. P., Lin, X. J., Zhang, Y. Q., Chen, M. S., Zhang, C. Q., . . . Li, J. Q. (2007). Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 245(1), 36-43. doi:10.1097/01.sla.0000231758.07868.71

Shi, M., Zhang, C. Q., Zhang, Y. Q., Liang, X. M., & Li, J. Q. (2004). Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg, 28(4), 376-381. doi:10.1007/s00268-003-7308-x

Shibata, T., Isoda, H., Hirokawa, Y., Arizono, S., Shimada, K., & Togashi, K. (2009). Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology, 252(3), 905-913. doi:2523081676 [pii]

10.1148/radiol.2523081676

Shih, W. L., Chang, H. C., Liaw, Y. F., Lin, S. M., Lee, S. D., Chen, P. J., . . . Yu, M. W. (2012). Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer, 131(11), 2612-2621. doi:10.1002/ijc.27508

Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., . . . Koike, K. (2012). Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol, 107(4), 569-577; quiz 578. doi:10.1038/ajg.2011.425

Silva, J. P., Berger, N. G., Tsai, S., Christians, K. K., Clarke, C. N., Mogal, H., . . . Gamblin, T. C. (2017). Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford), 19(8), 659-666. doi:10.1016/j.hpb.2017.04.016

Silveira, M. G., Suzuki, A., & Lindor, K. D. (2008). Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology, 48(4), 1149-1156. doi:10.1002/hep.22458

Singal, A., Volk, M. L., Waljee, A., Salgia, R., Higgins, P., Rogers, M. A., & Marrero, J. A. (2009). Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 30(1), 37-47. doi:10.1111/j.1365-2036.2009.04014.x

Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M., & Schoenfeld, P. S. (2010). A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol, 8(3), 280-288, 288 e281. doi:10.1016/j.cgh.2009.11.018

Singh, A. K., Kumar, R., & Pandey, A. K. (2018). Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med, 12, 9-26. doi:10.2174/2213988501812010009

Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010). Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51(5), 1820-1832. doi:10.1002/hep.23594

Steel, J., Baum, A., & Carr, B. (2004). Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology, 13(2), 73-79. doi:10.1002/pon.725

Sternby Eilard, M., Hagstrom, H., Mortensen, K. E., Wilsgaard, T., Vagnildhaug, O. M., Dajani, O., . . . Rizell, M. (2018). Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int, 38(5), 885-894. doi:10.1111/liv.13593

Sternby Eilard, M., Holmberg, E., Naredi, P., Soderdahl, G., & Rizell, M. (2018). Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. Scand J Gastroenterol, 53(8), 976-983. doi:10.1080/00365521.2018.1488180

Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018). Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther, 48(7), 696-703. doi:10.1111/apt.14937

Strasberg, S. M. (2005). Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg, 12(5), 351-355. doi:10.1007/s00534-005-0999-7

Strauss, R., Torner, A., Duberg, A. S., Hultcrantz, R., & Ekdahl, K. (2008). Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden - a low endemic country. J Viral Hepat, 15(7), 531-537. doi:10.1111/j.1365-2893.2008.00979.x

Sun, C. A., Wu, D. M., Lin, C. C., Lu, S. N., You, S. L., Wang, L. Y., . . . Chen, C. J. (2003). Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol, 157(8), 674-682. 

Takagi, K., Umeda, Y., Yoshida, R., Nobuoka, D., Kuise, T., Fushimi, T., . . . Yagi, T. (2018). Preoperative Controlling Nutritional Status Score Predicts Mortality after Hepatectomy for Hepatocellular Carcinoma. Dig Surg. doi:10.1159/000488215

Takeda, A., Sanuki, N., Eriguchi, T., Kobayashi, T., Iwabutchi, S., Matsunaga, K., . . . Kunieda, E. (2014). Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol, 29(2), 372-379. doi:10.1111/jgh.12350

Tanaka, K., Shimada, H., Matsumoto, C., Matsuo, K., Nagano, Y., Endo, I., & Togo, S. (2008). Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery, 143(5), 607-615. doi:10.1016/j.surg.2008.01.006

Tanaka, S., & Arii, S. (2009). Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci, 100(1), 1-8. doi:10.1111/j.1349-7006.2008.01006.x

Tandon, P., Ismond, K. P., Riess, K., Duarte-Rojo, A., Al-Judaibi, B., Dunn, M. A., . . . McNeely, M. (2018). Exercise in cirrhosis: Translating evidence and experience to practice. J Hepatol, 69(5), 1164-1177. doi:10.1016/j.jhep.2018.06.017

Tansel, A., Katz, L. H., El-Serag, H. B., Thrift, A. P., Parepally, M., Shakhatreh, M. H., & Kanwal, F. (2017). Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 15(8), 1207-1217 e1204. doi:10.1016/j.cgh.2017.02.006

Taouli, B., Goh, J. S., Lu, Y., Qayyum, A., Yeh, B. M., Merriman, R. B., & Coakley, F. V. (2005). Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr, 29(4), 425-429. 

Terzi, E., Iavarone, M., Pompili, M., Veronese, L., Cabibbo, G., Fraquelli, M., . . . collaborators, C. L.-R. I. s. g. (2018). Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol, 68(3), 485-492. doi:10.1016/j.jhep.2017.11.007

Teufel, A., Weinmann, A., Centner, C., Piendl, A., Lohse, A. W., Galle, P. R., & Kanzler, S. (2009). Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol, 15(5), 578-582. 

Thomas, M. B. (2008). Systemic therapy for hepatocellular carcinoma. Cancer J, 14(2), 123-127. doi:10.1097/PPO.0b013e31816a6058

Thompson Coon, J., Rogers, G., Hewson, P., Wright, D., Anderson, R., Cramp, M., . . . Stein, K. (2007). Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess, 11(34), 1-206. 

Toso, C., Meeberg, G., Hernandez-Alejandro, R., Dufour, J. F., Marotta, P., Majno, P., & Kneteman, N. M. (2015). Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology, 62(1), 158-165. doi:10.1002/hep.27787

Tran, T. T. (2009). Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med, 76 Suppl 3, S25-29. doi:10.3949/ccjm.76.s3.06

Trevisani, F., De Notariis, S., Rapaccini, G., Farinati, F., Benvegnu, L., Zoli, M., . . . Italian Liver Cancer, G. (2002). Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol, 97(3), 734-744. doi:10.1111/j.1572-0241.2002.05557.x

Trinchet, J. C. (2011). Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life. J Hepatol, 54(6), 1310-1311. doi:10.1016/j.jhep.2010.11.036

Tsai, W. L., & Chung, R. T. (2010). Viral hepatocarcinogenesis. Oncogene, 29(16), 2309-2324. doi:10.1038/onc.2010.36

Tuominen, L., Stolt, M., Meretoja, R., & Leino-Kilpi, H. (2018). Effectiveness of nursing interventions among patients with cancer: An overview of systematic reviews. J Clin Nurs. doi:10.1111/jocn.14762

Turati, F., Galeone, C., Rota, M., Pelucchi, C., Negri, E., Bagnardi, V., . . . La Vecchia, C. (2014). Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol, 25(8), 1526-1535. doi:10.1093/annonc/mdu020

Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., . . . Singal, A. G. (2018). Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 154(6), 1706-1718 e1701. doi:10.1053/j.gastro.2018.01.064

Wakabayashi, G., Cherqui, D., Geller, D. A., Buell, J. F., Kaneko, H., Han, H. S., . . . Strasberg, S. M. (2015). Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg, 261(4), 619-629. doi:10.1097/sla.0000000000001184

Wang, J. H., Chang, K. C., Kee, K. M., Chen, P. F., Yen, Y. H., Tseng, P. L., . . . Lu, S. N. (2013). Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol, 108(3), 416-424. doi:10.1038/ajg.2012.445

Wang, Y. B., Chen, M. H., Yan, K., Yang, W., Dai, Y., & Yin, S. S. (2007). Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res, 16(3), 389-397. doi:10.1007/s11136-006-9133-9

Ward, Z., Platt, L., Sweeney, S., Hope, V. D., Maher, L., Hutchinson, S., . . . Vickerman, P. (2018). Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Addiction. doi:10.1111/add.14217

Vauthey, J. N., Lauwers, G. Y., Esnaola, N. F., Do, K. A., Belghiti, J., Mirza, N., . . . Nagorney, D. M. (2002). Simplified staging for hepatocellular carcinoma. J Clin Oncol, 20(6), 1527-1536. 

Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., . . . Dore, G. J. (2017). Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol, 67(6), 1204-1212. doi:10.1016/j.jhep.2017.07.025

Wee, A. (2006). Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol, 14(3), 266-272. 

Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J. D., Cunningham, D., . . . van de Velde, C. (2009). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol, 20 Suppl 7, vii1-vii6. doi:10.1093/annonc/mdp281

White, D. L., Kanwal, F., & El-Serag, H. B. (2012). Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol, 10(12), 1342-1359 e1342. doi:10.1016/j.cgh.2012.10.001

Vilana, R., Forner, A., Bianchi, L., Garcia-Criado, A., Rimola, J., de Lope, C. R., . . . Bruix, J. (2010). Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology, 51(6), 2020-2029. doi:10.1002/hep.23600

Wildner, D., Bernatik, T., Greis, C., Seitz, K., Neurath, M. F., & Strobel, D. (2015). CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med, 36(2), 132-139. doi:10.1055/s-0034-1399147

Wildner, D., Pfeifer, L., Goertz, R. S., Bernatik, T., Sturm, J., Neurath, M. F., & Strobel, D. (2014). Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med, 35(6), 522-527. doi:10.1055/s-0034-1385170

Vilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G. P., . . . Group, S. T. (2017). Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol, 18(12), 1624-1636. doi:10.1016/S1470-2045(17)30683-6

Villanueva, A., Newell, P., & Hoshida, Y. (2010). Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 24(5), 725-734. doi:10.1016/j.bpg.2010.07.008

Wilson, S. R., Lyshchik, A., Piscaglia, F., Cosgrove, D., Jang, H. J., Sirlin, C., . . . Kono, Y. (2018). CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol (NY), 43(1), 127-142. doi:10.1007/s00261-017-1250-0

Vitale, A., Saracino, E., Boccagni, P., Brolese, A., D'Amico, F., Gringeri, E., . . . Cillo, U. (2009). Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc, 41(4), 1260-1263. doi:10.1016/j.transproceed.2009.03.054

Vivarelli, M., Cucchetti, A., La Barba, G., Ravaioli, M., Del Gaudio, M., Lauro, A., . . . Pinna, A. D. (2008). Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg, 248(5), 857-862. doi:10.1097/SLA.0b013e3181896278

Wong, G. L., Chan, H. L., Tse, Y. K., Chan, H. Y., Tse, C. H., Lo, A. O., & Wong, V. W. (2014). On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology, 59(3), 986-995. doi:10.1002/hep.26739

Wong, V. W., Chan, R. S., Wong, G. L., Cheung, B. H., Chu, W. C., Yeung, D. K., . . . Chan, H. L. (2013). Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol, 59(3), 536-542. doi:10.1016/j.jhep.2013.04.013

Wong, V. W., & Janssen, H. L. (2015). Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol, 63(3), 722-732. doi:10.1016/j.jhep.2015.05.019

Wood, L. S. (2009). Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs, 13 Suppl, 13-18. doi:10.1188/09.CJON.S2.13-18

Wood, L. S., & Manchen, B. (2007). Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs, 11(5), 649-656. doi:10.1188/07.CJON.649-656

Worns, M. A., Weinmann, A., Schuchmann, M., & Galle, P. R. (2009). Systemic therapies in hepatocellular carcinoma. Dig Dis, 27(2), 175-188. doi:10.1159/000218351

Wu, F., Wang, Z. B., Chen, W. Z., Zou, J. Z., Bai, J., Zhu, H., . . . Su, H. B. (2005). Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology, 235(2), 659-667. doi:235/2/659 [pii]10.1148/radiol.2352030916

Wu, X. M., Wang, J. F., Ji, J. S., Chen, M. G., & Song, J. G. (2017). Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther, 10, 1637-1643. doi:10.2147/ott.S115568

Xi, T., Lai, E. C., Min, A. R., Shi, L. H., Wu, D., Xue, F., . . . Wu, M. C. (2012). Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepato-gastroenterology, 59(116), 1198-1203. doi:10.5754/hge09654

Xiong, J. J., Altaf, K., Javed, M. A., Huang, W., Mukherjee, R., Mai, G., . . . Hu, W. M. (2012). Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. World J Gastroenterol, 18(45), 6657-6668. doi:10.3748/wjg.v18.i45.6657

Yamamoto, M., Takasaki, K., Ohtsubo, T., Katsuragawa, H., Fukuda, C., & Katagiri, S. (2001). Effectiveness of systematized hepatectomy with Glisson's pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery, 130(3), 443-448. doi:10.1067/msy.2001.116406

Yamashiki, N., Tateishi, R., Yoshida, H., Shiina, S., Teratani, T., Sato, S., . . . Omata, M. (2005). Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. Liver Transpl, 11(5), 508-514. doi:10.1002/lt.20392

Yamashita, Y., Hamatsu, T., Rikimaru, T., Tanaka, S., Shirabe, K., Shimada, M., & Sugimachi, K. (2001). Bile leakage after hepatic resection. Ann Surg, 233(1), 45-50. 

Yan, S., Xu, D., & Sun, B. (2012). Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci, 57(11), 3026-3031. doi:10.1007/s10620-012-2212-6

Yang, B., Li, C. L., Guo, W. H., Qin, T. Q., Jiao, H., Fei, Z. J., . . . Liao, Z. Y. (2018). Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer, 18(1), 101. doi:10.1186/s12885-018-3989-2

Yang, M., Fang, Z., Yan, Z., Luo, J., Liu, L., Zhang, W., . . . Liu, Q. (2014). Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol, 140(2), 211-219. doi:10.1007/s00432-013-1568-0

Yao, F. Y., Kinkhabwala, M., LaBerge, J. M., Bass, N. M., Brown, R., Jr., Kerlan, R., . . . Roberts, J. P. (2005). The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant, 5(4 Pt 1), 795-804. doi:10.1111/j.1600-6143.2005.00750.x

Yao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., . . . Roberts, J. P. (2015). Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology, 61(6), 1968-1977. doi:10.1002/hep.27752

Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. Checkmate 459: A randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (AHCC). Annals of oncology. 2019;30.

Ye, J. Z., Zhang, Y. Q., Ye, H. H., Bai, T., Ma, L., Xiang, B. D., & Li, L. Q. (2014). Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol, 20(45), 17141-17147. doi:10.3748/wjg.v20.i45.17141

Yeh, C. N., Chen, M. F., Lee, W. C., & Jeng, L. B. (2002). Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol, 81(4), 195-202. doi:10.1002/jso.10178

Yeoman, A. D., Al-Chalabi, T., Karani, J. B., Quaglia, A., Devlin, J., Mieli-Vergani, G., . . . Heneghan, M. A. (2008). Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology, 48(3), 863-870. doi:10.1002/hep.22432

Yeung, Y. P., Lo, C. M., Liu, C. L., Wong, B. C., Fan, S. T., & Wong, J. (2005). Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol, 100(9), 1995-2004. doi:10.1111/j.1572-0241.2005.00229.x

Younes, R., & Bugianesi, E. (2018). Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol, 68(2), 326-334. doi:10.1016/j.jhep.2017.10.006

Young, J. Y., Rhee, T. K., Atassi, B., Gates, V. L., Kulik, L., Mulcahy, M. F., . . . Salem, R. (2007). Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol, 18(11), 1375-1382. doi:18/11/1375 [pii]

10.1016/j.jvir.2007.07.016

Young, S., Taylor, A., Golzarian, J., Flanagan, S., D'Souza, D., & Sanghvi, T. (2019). Clinical utility of one month imaging following selective internal radiation therapy. Diagn Interv Imaging, 100(1), 39-46. doi:10.1016/j.diii.2018.07.005

Yu, J. I., Choi, G. S., Lim, D. H., Lee, E., Joh, J. W., Kwon, C. H. D., . . . Park, H. C. (2018). Treatment of Naive HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection Versus TACE Followed by Radiotherapy. Anticancer Res, 38(8), 4919-4925. doi:10.21873/anticanres.12808

Yu, N. C., Chaudhari, V., Raman, S. S., Lassman, C., Tong, M. J., Busuttil, R. W., & Lu, D. S. (2011). CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol, 9(2), 161-167. doi:10.1016/j.cgh.2010.09.017

Zhang, X., Wang, K., Wang, M., Yang, G., Ye, X., Wu, M., & Cheng, S. (2017). Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget, 8(17), 29416-29427. doi:10.18632/oncotarget.15075

Zhang, X. P., Wang, K., Li, N., Zhong, C. Q., Wei, X. B., Cheng, Y. Q., . . . Cheng, S. Q. (2017). Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer, 17(1), 902. doi:10.1186/s12885-017-3895-z

Zhang, Y., Fan, W., Wang, Y., Lu, L., Fu, S., Yang, J., . . . Li, J. (2015). Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist, 20(12), 1417-1424. doi:10.1634/theoncologist.2015-0196

Zhao, Q., Zhu, K., Yue, J., Qi, Z., Jiang, S., Xu, X., . . . Wang, R. (2017). Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis. Ther Clin Risk Manag, 13, 21-31. doi:10.2147/tcrm.S126181

Zheng, Z., Liang, W., Milgrom, D. P., Zheng, Z., Schroder, P. M., Kong, N. S., . . . He, X. (2014). Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation, 97(2), 227-234. doi:10.1097/TP.0b013e3182a89383

Zhong, C., Guo, R. P., Li, J. Q., Shi, M., Wei, W., Chen, M. S., & Zhang, Y. Q. (2009). A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol, 135(10), 1437-1445. doi:10.1007/s00432-009-0588-2

Zhou, H., Ortiz-Pallardo, M. E., Ko, Y., & Fischer, H. P. (2000). Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer, 88(12), 2668-2676. 

Zhou, Y., Zhang, X., Wu, L., Ye, F., Su, X., Shi, L., & Li, B. (2013). Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC gastroenterology, 13, 51. doi:10.1186/1471-230X-13-51

Zhu, A. X., Park, J. O., Ryoo, B. Y., Yen, C. J., Poon, R., Pastorelli, D., Blanc, J. F., Chung, H. C., Baron, A. D., Pfiffer, T. E., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau, I., Chang, S. C., Abada, P. B., Yang, L., Schwartz, J. D., Kudo, M., … REACH Trial Investigators (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet. Oncology, 16(7), 859–870.

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., . . . investigators, K.-. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 19(7), 940-952. doi:10.1016/S1470-2045(18)30351-6

Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., Rau, K. M., Motomura, K., Ohno, I., Merle, P., Daniele, B., Shin, D. B., Gerken, G., Borg, C., Hiriart, J. B., Okusaka, T., … REACH-2 study investigators (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 20(2), 282–296.

Nästa kapitel
Bilaga 1 Flöde surveillanceenhet NUS (HCC-övervakning)